What the science says about your GLP-1 journey.
Everything you need to know about latest research on nutrition, side effects, and supplementation for GLP-1 journey.
Compounded GLP-1 ban: what the FDA proposal means for patients
The FDA proposes to permanently ban compounded semaglutide, tirzepatide, and liraglutide. Public comment closes June 29, 2026. Here is what patients need to know.
GLP-1 hair loss: what the latest research shows
Large-scale data on half a million GLP-1 users shows a real but modest increase in hair loss risk. Here is what is driving it and what you can do.
GLP-1 medications and mood: what research shows about anxiety, depression, and mental health
New genetic and real-world data suggest GLP-1 medications like semaglutide may reduce anxiety and depression risk - but there is a nuance worth knowing about.
Retatrutide TRIUMPH-1 results: the triple-G drug that beats Wegovy and Zepbound
Eli Lilly's retatrutide delivered 28.3% average weight loss in Phase 3 TRIUMPH-1 - more than any approved GLP-1 drug. Here is what the data actually shows.
Semaglutide and Alzheimer's: what the EVOKE trial failure actually means
Oral semaglutide showed no benefit in the EVOKE Alzheimer's trials. But researchers argue it may still work as prevention - and here is the evidence behind that claim.
Semaglutide and kidney disease: what the FLOW trial shows
The FLOW trial found semaglutide cut major kidney events by 24% and all-cause mortality by 20% in people with type 2 diabetes and chronic kidney disease. Here is what the data means.
Semaglutide for fatty liver disease: what the ESSENCE trial and FDA approval mean
The FDA approved Wegovy for MASH with liver fibrosis in 2025. The ESSENCE trial showed 63% MASH resolution. Here is what GLP-1 users with fatty liver need to know.
What GLP-1 patients need to know about muscle loss and protein intake
New ongoing research tracks muscle loss on GLP-1 medications and how protein intake can preserve strength. Here is what we know so far.
Semaglutide heart benefits independent of weight loss: SELECT trial findings
The Lancet SELECT trial prespecified analysis found semaglutide reduced major cardiac events by 20% across all adiposity levels - only one-third of the benefit was explained by weight loss.
GLP-1 drugs as addiction treatment: the substance-by-substance evidence
A BMJ study of 606,434 veterans found semaglutide cut opioid use disorder risk by 25% and drug-related deaths by 50%. Here is what the evidence shows for each addictive substance.
GLP-1 drugs and addiction: they stop cravings from forming
GLP-1 medications like semaglutide don't just reduce existing addiction cravings - a major VA study and new research suggest they may prevent new addictions from forming entirely.
Solutions for post-GLP-1 weight regain: what the research shows
70% of GLP-1 users quit within a year and most regain all lost weight within 18 months. New research from DDW 2026 points to emerging strategies that may change that.
GLP-1 gut microbiome: why some people respond better to GLP-1 drugs
A 2026 review in the Canadian Journal of Physiology finds your gut microbiome may explain why GLP-1 medications like semaglutide work better for some people than others.
GLP-1 medicines cut fat while preserving muscle function
Cell Reports Medicine study: tirzepatide drove 73% of weight loss from fat in mice, and human participants showed no decline in leg strength after 12 weeks on semaglutide.
FDA approves oral Wegovy pill: first oral GLP-1 for weight loss
FDA approved semaglutide 25 mg tablets (Wegovy pill) for weight loss in December 2025 - what the OASIS 4 trial showed and what it means for patients.
GLP-1 side effects: what the science actually shows
A comprehensive review of GLP-1 side effects from the Journal of Clinical Investigation: nausea rates, thyroid risk, retinopathy, psychiatric safety, and more.
Semaglutide and tirzepatide cardiovascular outcomes: real-world data
Nature Medicine study of 800,000+ patients shows semaglutide and tirzepatide provide comparable heart protection in real-world clinical practice.
Tirzepatide beats semaglutide in SURMOUNT-5 head-to-head trial
SURMOUNT-5 trial data: tirzepatide produced 20.2% weight loss vs 13.7% for semaglutide over 72 weeks - what the numbers mean for you.
Semaglutide vs tirzepatide: what the 2026 clinical trials actually show
STEP and SURMOUNT trial data compared side by side: what semaglutide and tirzepatide actually produced in controlled studies, and why real-world results often fall short of the headlines.
Beyond GLP-1: researchers test a new approach to weight loss
Scientists behind the original GLP-1 drugs are now testing a GIP and glucagon-only molecule that may match semaglutide's weight loss without the nausea - but the evidence is still pre-clinical.
The GLP-1 stigma paradox: losing weight may not end the judgment
A Rice University study in the International Journal of Obesity found GLP-1 medication users face more social stigma than people who lost weight through diet alone - or didn't lose weight at all.
Oral GLP-1 drugs penetrate the brain to suppress cravings
A May 2026 NIH-funded Nature study found oral small-molecule GLP-1 drugs like Foundayo activate deep brain reward circuits, reducing pleasure-driven eating and potentially addiction cravings.
What's ahead for GLP-1 medications in 2026
From oral pills to Medicare access and next-gen triple agonists, 2026 is shaping up as the biggest year yet for GLP-1 medications like Ozempic, Wegovy, and tirzepatide.
What vitamins are you deficient in on GLP-1 medications?
GLP-1 medications like Ozempic and Wegovy shrink your appetite - but research shows they may also leave critical nutrient gaps that most patients never hear about.
Muscle loss on GLP-1 medications: what the research actually shows
Losing muscle on Ozempic or Wegovy? New data from Cell Reports Medicine shows fat - not muscle - accounts for most GLP-1 weight loss, but the full picture is more nuanced.
What happens when you stop taking Ozempic or Wegovy?
Stopping semaglutide or tirzepatide leads to rapid weight regain for most people - research shows up to two-thirds of lost weight returns within a year. Here is what to do about it.
How many people qualify for GLP-1 medications worldwide?
A Lancet study of 810,635 adults across 99 countries found 27% of global adults qualify for GLP-1 therapy - but access remains deeply unequal.
Foundayo (orforglipron): the new oral GLP-1 pill - what patients need to know
FDA approved Foundayo (orforglipron) in April 2026 - the second oral GLP-1 for weight loss. Here is what it does, how it differs from Wegovy pill, and who it suits.
Why some people respond better to GLP-1 drugs: the gut microbiome connection
Your gut microbiome may predict how well semaglutide or tirzepatide works for you. New research explains the bacteria-GLP-1 link and what you can do about it.
Berberine: nature's Ozempic - what the evidence actually shows
Berberine is called nature's Ozempic, but does it actually work like semaglutide? UCLA Health dietitians and clinical trial data give a more honest answer.
How GLP-1 medications reduce addiction and cravings: the neuroscience
GLP-1 medications like Ozempic and semaglutide are showing striking effects on alcohol, nicotine, and opioid cravings. Here is what the neuroscience actually explains.
Medicare GLP-1 coverage 2026: what the $50 bridge program means for you
Medicare's GLP-1 Bridge program launches July 1, 2026, capping Wegovy and Zepbound at $50/month. Here is who qualifies, what is covered, and what the catch is.
What GLP-1 patients need to know about muscle loss and protein intake
New ongoing research tracks muscle loss on GLP-1 medications and how protein intake can preserve strength. Here's what we know so far.
What we know about nutrient deficiency on GLP-1 medications right now
New research on GLP-1 medications like Ozempic and Wegovy reveals how nutrient deficiency and muscle loss affect patients. Here's what an ongoing trial is finding.
GLP-1 medications and your gut microbiome: early findings on nutrient absorption
New research suggests GLP-1 drugs may alter gut bacteria, with potential effects on B vitamin and SCFA production - an under-explored nutritional angle.
Fat-soluble vitamins and GLP-1: an overlooked deficiency risk
Emerging research suggests GLP-1 medications may reduce absorption of vitamins A, D, E, and K more than commonly recognized.
The GLP-1 and gut microbiome loop: what it means for your nutrients
New research reveals a two-way street between GLP-1 drugs and gut bacteria - with real implications for vitamin and mineral levels.
Bone health on GLP-1 medications: what the latest research reveals
New studies show semaglutide and tirzepatide may affect bone density. Here's what long-term patients need to know.
The vitaglp trial: can a multivitamin fix GLP-1 nutrient gaps?
A new clinical trial tests whether multivitamins correct micronutrient deficiencies in GLP-1 patients. Here's what it means for you.
The GLP-1 trial midlife women are waiting for: muscle, bone, and estrogen
A new clinical trial is recruiting to study how GLP-1 medications affect muscle and bone in women over 40. Here's what we know now and what you can do today.
No articles in this category yet.